# Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

> **NCT05474053** · PHASE3 · COMPLETED · sponsor: **Cairo University** · enrollment: 29 (actual)

## Conditions studied

- Cardiovascular Diseases
- Acute Coronary Syndrome

## Interventions

- **DRUG:** Ticagrelor 90mg (Brilique)
- **DRUG:** Ticagrelor 90mg (Ticaloguard)

## Key facts

- **NCT ID:** NCT05474053
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-13
- **Primary completion:** 2021-11-28
- **Final completion:** 2021-11-28
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05474053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05474053, "Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05474053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*